ERBB2 and neoplasm: Overexpression of HER2 leads to the constitutive activation of different EGFR signaling pathways, i.e., the PI3K/AKT/mTOR and RAS-RAF-MEK-ERK pathways, which when overly activated lead to oncogenic transformation and tumor progression [11].